Cart (0)
business newsETFs for Biotech M&A Mania
Lost in the whirlwind of economic data, bailout news last week was a noticeable uptick in mergers and acquisitions activity in the biotech sector. Here, the best ETF plays.
PRINT
 |
|
Lost in the whirlwind of economic data and bailout news last week was a noticeable uptick in mergers and acquisitions activity in the biotech sector, a group that is seemingly always home to a good trade-worthy rumor or two.
According to Minyanville, in a two-day span last week, roughly $3.1 billion in biotech-related deals were announced and there's probably more to come as the biotech sector remains an investment banker's dream. (See Drug Fever Rising.)
Stodgy Big Pharma companies such as Pfizer (PFE) and Merck (MRK) are facing patent cliffs, shallow pipelines bereft of blockbuster drugs and desperately need access to the emerging markets.Enter biotech. Big Pharma is on the hunt "for treatments for cancer, nervous system disorders, heart conditions, metabolic and immune system conditions as well as other diseases," Minyanville reported.
With that, identifying the best ETF plays for biotech M&A is quite easy.
1. PowerShares Dynamic Biotech & Genome ETF (PBE):
Companies that are working on treatments for genetic disorders are hot commodities these days and that explains Sanofi-Aventis's (SNE) $18.5 billion hostile takeover bid for Genzyme (GENZ).
While Genzyme isn't found among PBE's top-10 holdings according to the most recent data, there are some compelling targets in PBE's fray.
Alexion Pharmaceuticals (ALXN) is a cancer-treatment play with a reasonable market cap of just under $7 billion, and Neurocrine Biosciences (NBIX) is a small-cap play on emotional disorders, among other health issues. With a market cap of less than $800 million, Neurocrine could be another target for Big Pharma.2. iShares Nasdaq Biotechnology ETF (IBB):
IBB is perhaps the most popular, and therefore one of the more liquid biotech ETFs. Home to 131 stocks, IBB exposures investors and traders to both buyers and potential targets in the biotech M&A game.
Amgen (AMGN), a potential buyer, accounts for 8% of IBB, but targets such as Alexion and Genzyme can also be found among the ETF's top-10 holdings.
IBB very well could be the most sound option for the patient biotech investor due to its good mix of stocks and emphasis on less speculative fare.
3. SPDR S&P Biotech ETF (XBI):
Home to about 30 stocks, XBI offers exposure to biotech big boys like Amgen and Gilead Sciences (GILD), but the ETF can be viewed as an interesting way of getting exposure to increased biotech M&A activity because small- and mid-cap names dominate the top-10 holdings.
Alexion is the fourth-largest holding and Myriad Genetics (MYGN), another genetics play obviously, accounts for almost 4.4% of the ETF.
Theravance (THRX), which is working on treatments for respiratory disease, bacterial infections, and gastrointestinal motility dysfunction, is XBI's top holding.
For more on ETFs take a FREE 14 day trial to the Grail ETF & Equity Investor newsletter. Ron Coby & Denny Lamson use their proprietary Grail indicator to find ETFs poised for big moves. Learn more.
Below, find some more great ETF and market content from Benzinga:
The Not-So Stealth Rally in Uranium
By The ETF Professor
5 Stocks to Own in Preparation for QE3
By Scott Rubin
Unemployment Shell Game?
By Donald Susswein
The information on this website solely reflects the analysis of or opinion about the performance of securities and financial markets by the writers whose articles appear on the site. The views expressed by the writers are not necessarily the views of Minyanville Media, Inc. or members of its management. Nothing contained on the website is intended to constitute a recommendation or advice addressed to an individual investor or category of investors to purchase, sell or hold any security, or to take any action with respect to the prospective movement of the securities markets or to solicit the purchase or sale of any security. Any investment decisions must be made by the reader either individually or in consultation with his or her investment professional. Minyanville writers and staff may trade or hold positions in securities that are discussed in articles appearing on the website. Writers of articles are required to disclose whether they have a position in any stock or fund discussed in an article, but are not permitted to disclose the size or direction of the position. Nothing on this website is intended to solicit business of any kind for a writer's business or fund. Minyanville management and staff as well as contributing writers will not respond to emails or other communications requesting investment advice.
Copyright 2011 Minyanville Media, Inc. All Rights Reserved.
